How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

In the business world, one company's pain can mean another company's gain. You can double that with recent developments in the COVID-19 vaccine market.

AstraZeneca (NASDAQ:AZN) has stumbled quite a bit in recent months with its COVID-19 vaccine program. There was a new development just last week that could further complicate matters for the big drugmaker. Also last week, German biotech CureVac (NASDAQ:CVAC) reported a serious setback for its COVID-19 vaccine hopes.